Grifols (GRFS) Revenue & Revenue Breakdown
Grifols Revenue Highlights
Latest Revenue (Y)
$6.59B
Latest Revenue (Q)
$1.63B
Main Segment (Y)
Haemoderivatives
Main Geography (Y)
USA and Canada
Grifols Revenue by Period
Grifols Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $6.59B | 8.71% |
| 2022-12-31 | $6.06B | 22.92% |
| 2021-12-31 | $4.93B | -7.62% |
| 2020-12-31 | $5.34B | 4.73% |
| 2019-12-31 | $5.10B | 13.64% |
| 2018-12-31 | $4.49B | 3.91% |
| 2017-12-31 | $4.32B | 6.62% |
| 2016-12-31 | $4.05B | 2.93% |
| 2015-12-31 | $3.93B | 17.26% |
| 2014-12-31 | $3.36B | 22.38% |
| 2013-12-31 | $2.74B | 4.61% |
| 2012-12-31 | $2.62B | 45.96% |
| 2011-12-31 | $1.80B | 81.24% |
| 2010-12-31 | $990.73M | 8.49% |
| 2009-12-31 | $913.19M | 12.14% |
| 2008-12-31 | $814.31M | 15.79% |
| 2007-12-31 | $703.29M | 8.40% |
| 2006-12-31 | $648.80M | 23.75% |
| 2005-12-31 | $524.28M | - |
Grifols generated $6.59B in revenue during NA 2023, up 8.71% compared to the previous quarter, and up 146.92% compared to the same period a year ago.
Grifols Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.63B | -8.13% |
| 2023-12-31 | $1.77B | 10.77% |
| 2023-09-30 | $1.60B | -3.97% |
| 2023-06-30 | $1.66B | 7.83% |
| 2023-03-31 | $1.54B | -9.93% |
| 2022-12-31 | $1.71B | 11.14% |
| 2022-09-30 | $1.54B | -0.11% |
| 2022-06-30 | $1.54B | 21.76% |
| 2022-03-31 | $1.27B | 5.75% |
| 2021-12-31 | $1.20B | - |
| 2021-09-30 | $1.20B | -11.37% |
| 2021-06-30 | $1.35B | 14.11% |
| 2021-03-31 | $1.18B | -9.52% |
| 2020-12-31 | $1.31B | -3.25% |
| 2020-09-30 | $1.35B | -2.21% |
| 2020-06-30 | $1.38B | 7.01% |
| 2020-03-31 | $1.29B | -4.97% |
| 2019-12-31 | $1.36B | 3.54% |
| 2019-09-30 | $1.31B | 3.78% |
| 2019-06-30 | $1.27B | 9.49% |
| 2019-03-31 | $1.16B | -5.40% |
| 2018-12-31 | $1.22B | 6.91% |
| 2018-09-30 | $1.14B | 4.26% |
| 2018-06-30 | $1.10B | 7.24% |
| 2018-03-31 | $1.02B | -4.20% |
| 2017-12-31 | $1.07B | 0.96% |
| 2017-09-30 | $1.06B | -6.46% |
| 2017-06-30 | $1.13B | 6.51% |
| 2017-03-31 | $1.06B | -3.32% |
| 2016-12-31 | $1.10B | 9.81% |
| 2016-09-30 | $1.00B | 0.74% |
| 2016-06-30 | $992.71M | 3.52% |
| 2016-03-31 | $958.93M | -9.77% |
| 2015-12-31 | $1.06B | 9.43% |
| 2015-09-30 | $971.20M | -2.11% |
| 2015-06-30 | $992.18M | 9.22% |
| 2015-03-31 | $908.38M | -0.97% |
| 2014-12-31 | $917.29M | 10.88% |
| 2014-09-30 | $827.31M | 1.79% |
| 2014-06-30 | $812.78M | 16.92% |
| 2013-12-31 | $695.17M | 4.42% |
| 2013-09-30 | $665.72M | -4.51% |
| 2013-06-30 | $697.14M | 5.40% |
| 2012-12-31 | $661.43M | 2.90% |
| 2012-09-30 | $642.81M | -1.11% |
| 2012-06-30 | $650.02M | 10.16% |
| 2011-12-31 | $590.07M | 3.49% |
| 2011-09-30 | $570.20M | 52.50% |
| 2011-06-30 | $373.91M | 48.43% |
| 2010-12-31 | $251.91M | 30.44% |
| 2010-09-30 | $193.12M | - |
Grifols generated $1.63B in revenue during Q1 2024, up -8.13% compared to the previous quarter, and up 94.92% compared to the same period a year ago.
Grifols Revenue Breakdown
Grifols Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Other Product | $203.45M | $250.16M | $39.62M | - | - |
| Other diagnostic | $21.79M | $21.74M | $23.63M | - | - |
| Transfusional medicine | $648.48M | $640.60M | $712.24M | - | - |
| Bio supplies | $159.96M | $146.08M | $225.76M | - | - |
| Haemoderivatives | $5.56B | $5.01B | $3.81B | $4.24B | $3.99B |
| Fluid therapy and nutrition | - | - | $46.67M | - | - |
| Hospital supplies | - | - | $70.22M | - | - |
| Bio Supplies Product | - | - | - | $224.09M | $266.54M |
| Transfusional Medicine | - | - | - | $714.16M | $680.77M |
| Others Product | - | - | - | $31.99M | $22.82M |
| Other Diagnostic | - | - | - | $27.63M | $19.94M |
| Hospital Supplies | - | - | - | $58.30M | $67.49M |
| Fluid Therapy And Nutrition | - | - | - | $41.36M | $47.68M |
Grifols's latest annual revenue breakdown by segment (product or service), as of Dec 23: Haemoderivatives (84.32%), Transfusional medicine (9.84%), Other Product (3.09%), Bio supplies (2.43%), and Other diagnostic (0.33%).
Grifols Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| European Union | $893.05M | $711.58M | $544.04M | - | - |
| USA and Canada | $3.90B | $3.86B | $3.15B | - | - |
| Spain | $362.88M | $320.63M | $362.41M | - | - |
| Rest of the world | $1.44B | $1.18B | $872.12M | - | - |
| Country Of Domicile | - | - | - | $339.17M | $268.29M |
| United States And Canada | - | - | - | $3.60B | $3.39B |
| Rest Of World | - | - | - | $905.80M | $851.22M |
| European Union Excluding Spain | - | - | - | $495.32M | $588.38M |
Grifols's latest annual revenue breakdown by geography, as of Dec 23: USA and Canada (59.15%), Rest of the world (21.80%), European Union (13.55%), and Spain (5.50%).
Grifols Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MRK | Merck | $60.12B | $16.11B |
| NVS | Novartis | $46.66B | $11.83B |
| AZN | AstraZeneca | $45.81B | $12.68B |
| BMY | Bristol-Myers Squibb Company | $45.01B | $11.89B |
| SNY | Sanofi | $43.07B | $11.12B |
| GSK | GSK | $30.33B | $7.36B |
| AMGN | Amgen | $28.19B | $8.50B |
| GILD | Gilead Sciences | $27.12B | $6.95B |
| BIIB | Biogen | $9.84B | $2.47B |
| GRFS | Grifols | $6.59B | $1.63B |
GRFS Revenue FAQ
What is Grifols’s yearly revenue?
Grifols's yearly revenue for 2023 was $6.59B, representing an increase of 8.71% compared to 2022. The company's yearly revenue for 2022 was $6.06B, representing an increase of 22.92% compared to 2021. GRFS's yearly revenue for 2021 was $4.93B, representing a decrease of -7.62% compared to 2020.
What is Grifols’s quarterly revenue?
Grifols's quarterly revenue for Q1 2024 was $1.63B, a -8.13% decrease from the previous quarter (Q4 2023), and a 5.38% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.77B, a 10.77% increase from the previous quarter (Q3 2023), and a 3.32% increase year-over-year (Q4 2022). GRFS's quarterly revenue for Q3 2023 was $1.6B, a -3.97% decrease from the previous quarter (Q2 2023), and a 3.66% increase year-over-year (Q3 2022).
What is Grifols’s revenue growth rate?
Grifols's revenue growth rate for the last 3 years (2021-2023) was 33.63%, and for the last 5 years (2019-2023) was 29.29%.
What are Grifols’s revenue streams?
Grifols's revenue streams in c 23 are Other Product, Other diagnostic, Transfusional medicine, Bio supplies, and Haemoderivatives. Other Product generated $203.45M in revenue, accounting 3.09% of the company's total revenue, down -18.67% year-over-year. Other diagnostic generated $21.79M in revenue, accounting 0.33% of the company's total revenue, up 0.23% year-over-year. Transfusional medicine generated $648.48M in revenue, accounting 9.84% of the company's total revenue, up 1.23% year-over-year. Bio supplies generated $159.96M in revenue, accounting 2.43% of the company's total revenue, up 9.50% year-over-year. Haemoderivatives generated $5.56B in revenue, accounting 84.32% of the company's total revenue, up 11.05% year-over-year.
What is Grifols’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Grifols was Haemoderivatives. This segment made a revenue of $5.56B, representing 84.32% of the company's total revenue.